tulisokibart vs XmAb942

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: TL1A · full Ulcerative Colitis pipeline

tulisokibart

Developed by Merck & Co.

Phase 3 in Ulcerative Colitismonoclonal antibody (humanized)
Reliable signal

NCT06052059 · Phase 3 · active, not recruiting

First Ph3 induction win for any anti-TL1A; met primary + key secondaries (June 2026).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2037 · NCT06651281 (registry estimate)

Reported efficacy

Clinical remission (MMS) at week 12: ATLAS-UC Study 2 (NCT06052059): tulisokibart met its primary endpoint of clinical remission (Modified Mayo Score) at week 12, plus key secondary endpoints. (met)

Result source: NCT06052059

XmAb942

Developed by Xencor

Phase 1/2 in Ulcerative Colitismonoclonal antibody (long-acting anti-TL1A, Xtend half-life technology)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT06619990 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointtulisokibartXmAb942
Clinical remission (induction)26.5% vs 1.5%+25 vs placebowk 12 · n 68NCT04996797
1 other result
  • 31.6% vs 10.8% wk 12 · n 38 · Phase 2 · secondary NCT04996797
—Not reported
Clinical remission (maintenance)—Trial running · NCT06052059—Not reported
Clinical response (induction)66.2% vs 22.4%+43.8 vs placebowk 12 · n 68NCT04996797
1 other result
  • 55.3% vs 32.4% wk 12 · n 38 · Phase 2 · secondary NCT04996797
—Not reported
Endoscopic improvement (induction)36.8% vs 6%+30.8 vs placebowk 12 · n 68NCT04996797
1 other result
  • 36.8% vs 18.9% wk 12 · n 38 · Phase 2 · secondary NCT04996797
—Not reported
Corticosteroid-free remission (maintenance)—Trial running · NCT06052059—Not reported

Clinical remission (induction)

tulisokibart
26.5% vs 1.5%+25 vs placebowk 12 · n 68NCT04996797
1 other result
  • 31.6% vs 10.8% wk 12 · n 38 · Phase 2 · secondary NCT04996797
XmAb942
—Not reported

Clinical remission (maintenance)

tulisokibart
—Trial running · NCT06052059
XmAb942
—Not reported

Clinical response (induction)

tulisokibart
66.2% vs 22.4%+43.8 vs placebowk 12 · n 68NCT04996797
1 other result
  • 55.3% vs 32.4% wk 12 · n 38 · Phase 2 · secondary NCT04996797
XmAb942
—Not reported

Endoscopic improvement (induction)

tulisokibart
36.8% vs 6%+30.8 vs placebowk 12 · n 68NCT04996797
1 other result
  • 36.8% vs 18.9% wk 12 · n 38 · Phase 2 · secondary NCT04996797
XmAb942
—Not reported

Corticosteroid-free remission (maintenance)

tulisokibart
—Trial running · NCT06052059
XmAb942
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

XmAb942: no structured comparison results are available for Ulcerative Colitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. tulisokibart: 3 of 4 rows · XmAb942: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metrictulisokibart
Dropout rate
—All Cohorts (Cohort 1 & Cohort 2)
NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2
show 1 more result
n/a: no completion milestoneCohort 1 Tulisokibart
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
Discontinued due to AEs
—All Cohorts (Cohort 1 & Cohort 2)
NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2
show 1 more result
0%Cohort 1 Tulisokibart
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
Serious AEs
1.1%All Cohorts (Cohort 1 & Cohort 2)
NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2
show 1 more result
—Cohort 1 Tulisokibart
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
Most frequent reported AEs
covid-19 5.6% (placebo 4.5%)
NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

tulisokibart

Clinical Remission 26.5% (n=68) vs 1.5% (n=67) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
31.6% (n=38) vs 10.8% (n=37) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
Endoscopic Improvement 36.8% (n=68) vs 6% (n=67) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
36.8% (n=38) vs 18.9% (n=37) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
Clinical Response 66.2% (n=68) vs 22.4% (n=67) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
55.3% (n=38) vs 32.4% (n=37) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
Symptomatic Remission 19.1% (n=68) vs 6% (n=67) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
21.1% (n=38) vs 10.8% (n=37) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
Histologic Improvement 46.2% (n=65) vs 17.5% (n=57) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
55.6% (n=36) vs 26.7% (n=30) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
Histologic-Endoscopic Mucosal Improvement 30.8% (n=65) vs 3.5% (n=57) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
38.9% (n=36) vs 16.7% (n=30) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
Histologic-endoscopic Mucosal Healing 30.8% (n=65) vs 3.5% (n=57) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
38.9% (n=36) vs 16.7% (n=30) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
IBDQ 82.4% (n=68) vs 49.3% (n=67) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
76.3% (n=38) vs 56.8% (n=37) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: tulisokibart's landscape · XmAb942's landscape